BDB-001 + cyclophosphamide + azathioprine

This is a **combination regimen** consisting of three pharmaceuticals: - **BDB-001**, a recombinant human IgG4 monoclonal antibody that binds complement component C5a and inhibits C5a-triggered inflammation and cytokine storm, primarily developed for severe COVID-19 and other inflammatory diseases. Its mechanism is to specifically neutralize C5a, thereby blocking downstream proinflammatory effects without affecting C5 cleavage or membrane attack complex formation[1][7]. - **Cyclophosphamide**, an alkylating agent commonly used as an antineoplastic and immunosuppressive drug. Cyclophosphamide forms DNA cross-links, leading to cell death, and suppresses immune responses by inhibiting lymphocyte proliferation. - **Azathioprine**, an immunosuppressive antimetabolite that inhibits purine synthesis, leading to decreased proliferation of B and T lymphocytes and thus suppression of immune-mediated processes. This combination could hypothetically be explored in situations where immune suppression and anti-inflammatory modulation via complement blockade are beneficial. However, there is no known clinical precedent or established clinical trial for the precise combination of BDB-001, cyclophosphamide, and azathioprine together in a single regimen as of the latest available data.